Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 377 results
A drug compound in a glass vial on a lab bench with shelves of reagents in the background.

May 25, 2026

Machine learning brings speed to pharma’s slowest pipeline

Machine learning is revolutionizing the drug discovery process by enhancing efficiency in target identification and compound selection, yet it faces challenges in validation and integration with existing workflows.Recent research published in *Pharmaceuticals* emphasizes the transformative role of machine learning (ML) in drug discovery, particularly in the early stages where researchers select targets and evaluate molecular candidates. The study advocates for ML as a complementary tool to exper
A vial of medication on a lab bench

May 25, 2026

Can Nvidia’s Backing Reframe Generate Biomedicines (GENB) as a Scaled AI Drug Developer?

Nvidia's recent investment in Generate Biomedicines highlights a significant shift in the biotech landscape, particularly in AI-driven drug development. The $10.40 million funding aims to bolster Generate's clinical pipeline, which includes advanced therapies for severe asthma and oncology, currently under FDA Fast Track status.This investment not only validates Generate Biomedicines' approach but also emphasizes the growing traction of AI in real-world drug discovery. However, the company faces
A small-molecule drug compound on a lab bench in a biopharmaceutical lab

May 24, 2026

Redwood AI’s Data Boom and Defense Push Contrast With Silent Pharma Pact

Redwood AI is making strides in both the defense and pharmaceutical sectors, yet its stock remains volatile due to a lack of financial clarity.The Canadian AI company has recently announced a partnership with Resilience Biosciences, a biopharmaceutical firm focused on developing non-opioid therapies. This collaboration will utilize Redwood’s advanced software for designing small-molecule drug candidates. However, the absence of financial specifics in the announcement has left investors uncertain
A vial of enzyme sample on a lab bench with shelves of reagents in the background.

May 21, 2026

Imperagen’s £5M Bid Powers AI Enzyme Design Leap

Imperagen has secured £5 million in funding to enhance its AI-driven enzyme design platform, aiming to revolutionize the biocatalyst development landscape.The latest funding round brings Imperagen's total to £8.5 million since its inception in 2021, allowing the company to expand its research and development efforts in AI enzyme design. This financial boost will support hiring in key areas such as computational chemistry and automation, with plans to double its workforce within the next year. Th
A minimalist representation of an enzyme and chemical bond in dark colors with lime accents.

May 21, 2026

Manchester AI biotech spin-out lands £5m to “rewrite chemical reactions”

Manchester-based biotech spin-out Imperagen has successfully raised £5 million in seed funding to enhance its AI-driven enzyme engineering platform, a venture stemming from research conducted at The University of Manchester.This funding round, led by PXN Ventures with participation from existing investors IQ Capital and Northern Gritstone, brings Imperagen's total funding to £8.5 million. Established in 2021 by researchers Dr. Andrew Almond, Dr. Andrew Currin, and Dr. Tim Eyes, the company aims
A test tube with a colorful chemical solution in a dimly lit lab

May 21, 2026

Concept Life Science and OpenBench team up on AI-driven hit discovery platform for biotechs

Concept Life Sciences and OpenBench have formed a strategic alliance aimed at enhancing hit identification for biotech firms through an innovative fee-for-success model.This partnership merges OpenBench's AI-driven, structure-based discovery platform with Concept Life Sciences' expertise in medicinal chemistry and in-vitro screening. The collaboration promises to expedite the journey from target identification to validated hit series, potentially within a six-month timeframe. OpenBench's model a
A minimalist illustration of a molecule and a computer chip, symbolizing AI in drug discovery.

May 21, 2026

QIAGEN Partners with NVIDIA to Expand AI Drug Discovery

QIAGEN has announced a strategic partnership with NVIDIA to enhance AI-driven drug discovery and biomedical research.This collaboration aims to integrate NVIDIA's advanced computing capabilities and the BioNeMo platform into QIAGEN Digital Insights (QDI). By combining QIAGEN’s extensive biological and bioinformatics resources with NVIDIA's AI technologies, the partnership seeks to improve data analysis, biomarker discovery, and target identification throughout the drug development process.The in
A test tube with a colorful liquid sample in a laboratory setting

May 21, 2026

QIAGEN and NVIDIA partner on AI drug discovery

QIAGEN has announced a strategic partnership with NVIDIA to enhance AI-driven drug discovery through advanced computing and the BioNeMo platform, unveiled at the 2026 BIO-IT World Conference & Expo.This collaboration aims to merge QIAGEN’s extensive biomedical knowledge with cutting-edge artificial intelligence, thereby streamlining processes in drug discovery, target identification, and biomarker research. By leveraging this integration, pharmaceutical and biotechnology researchers will be bett
An enzyme sample on a lab surface in a dimly lit laboratory

May 21, 2026

Imperagen Raises €5.8M Seed for AI and Quantum Enzyme Engineering

Imperagen, a Manchester-based biotech firm, has secured €5.8 million in seed funding to enhance its innovative enzyme engineering platform, which utilizes AI and quantum simulation technologies.Recently, Imperagen announced the closing of a £5 million (~€5.8 million) seed funding round led by PXN Ventures, with participation from existing investors IQ Capital and Northern Gritstone. This funding brings the company's total investment to £8.5 million since its inception in 2021. The new capital wi
minimalist illustration of a drug compound

May 21, 2026

Concept Life Sciences Partners with OpenBench to Deliver Success-Based Drug Discovery Services for Early-Stage Biotech

Concept Life Sciences has formed a strategic alliance with OpenBench to enhance drug discovery services for early-stage biotech firms through a fee-for-success model.This collaboration integrates OpenBench's AI-driven discovery platform with Concept Life Sciences' expertise in medicinal chemistry and in-vitro screening. The partnership aims to expedite the process from target identification to validated hit series, potentially achieving this in just six months while alleviating upfront costs and
Flat illustration of an enzyme structure with quantum wave representation

May 21, 2026

Imperagen raises £5 million to use quantum physics, AI on enzyme engineering

Imperagen, a biotech startup focused on enzyme engineering, has successfully secured £5 million ($6.7 million) in seed funding, primarily from PXN Ventures, along with contributions from IQ Capital and Northern Gritstone. Established in 2021 by scientists from the Manchester Institute of Biotechnology, the company aims to revolutionize enzyme engineering by leveraging advanced technologies.To enhance the enzyme engineering process, Imperagen is adopting a novel approach that integrates quantum p
A glass vial containing an enzyme sample on a lab bench in a dimly lit laboratory.

May 21, 2026

Spin-out Imperagen raises £5m and announces new CEO

Imperagen, a Manchester-based life sciences spin-out, has successfully secured £5 million in seed funding to enhance its enzyme engineering capabilities through AI and quantum physics technologies.The funding round, led by PXN Ventures and supported by existing investors IQ Capital and Northern Gritstone, brings Imperagen's total funding to £8.5 million. This capital will enable the company to expand its research and development efforts, enhance its wet lab capabilities, and strengthen its marke